Editas Medicine, Inc. Common Stock vs. Halozyme Therapeutics, Inc.
EDIT
Editas Medicine, Inc. Common Stock
$2.70 -0.74%
VS HALOHalozyme Therapeutics, Inc.
$112.45 +2.53%
Halozyme Therapeutics, Inc. (HALO) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| EDIT | HALO | |
|---|---|---|
| Market Cap | $414.67 million | $12.76 billion |
| Revenue (TTM) | $47.01 million | $1.66 billion |
| Net Income (TTM) | $-73,949,000 | $413.60 million |
HALO leads on 3 of 3 size & scale factors.
Valuation
| EDIT | HALO | |
|---|---|---|
| P/E Ratio | — | 32.78 |
| Price / Book | 3.94 | 88.91 |
| Price / Sales | 8.82 | 7.67 |
EDIT and HALO split the valuation factors evenly.
Profitability
| EDIT | HALO | |
|---|---|---|
| Net Margin | -157.32% | 24.86% |
| Return on Equity | -70.24% | 288.13% |
HALO leads on 2 of 2 profitability factors.
Risk & Sentiment
| EDIT | HALO | |
|---|---|---|
| Short Interest | 4.06% | 9.79% |
EDIT leads on 1 of 1 risk & sentiment factors.
Dig deeper: EDIT overview, EDIT financials, HALO overview, HALO financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.